Search

Your search keyword '"Zimran, Eran"' showing total 4 results
Start Over Author "Zimran, Eran" Journal leukemia & lymphoma
4 results on '"Zimran, Eran"'

1. Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma

Author

Lebel, Eyal, primary, Goldschmidt, Neta, additional, Siegal, Tali, additional, Lossos, Alexander, additional, Rosenberg, Shai, additional, Makranz, Chen, additional, Linetski, Eduard, additional, Gatt, Moshe E., additional, Gural, Alexander, additional, Saban, Revital, additional, Lavie, David, additional, Vainstein, Vladimir, additional, Zimran, Eran, additional, Avni, Batia, additional, Grisaro, Sigal, additional, Shaulov, Adir, additional, and Nachmias, Boaz, additional

Published
2022
Full Text
View/download PDF

3. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

Author

Levy, Ilana, primary, Lavi, Avital, additional, Zimran, Eran, additional, Grisariu, Sigal, additional, Aumann, Shlomzion, additional, Itchaki, Gilad, additional, Berger, Tamar, additional, Raanani, Pia, additional, Harel, Reut, additional, Aviv, Ariel, additional, Lavi, Noa, additional, Zuckerman, Tsila, additional, Shvidel, Lev, additional, Jarchowsky, Osnat, additional, Ellis, Martin, additional, Herzog Tzarfati, Katrin, additional, Koren-Michowitz, Maya, additional, Sherf, Yehonatan, additional, Levi, Itai, additional, Sofer, Orit, additional, Shpilberg, Ofer, additional, Dally, Nagib, additional, Suriu, Celia, additional, Braester, Andrei, additional, Ben Barouch, Sharon, additional, Leiba, Merav, additional, Goldstein, Daniela, additional, Sarid, Nadav, additional, Yeganeh, Shay, additional, Halloun, Jabour, additional, Mittelman, Moshe, additional, and Tadmor, Tamar, additional

Published
2021
Full Text
View/download PDF

4. Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcome.

Author

Lebel, Eyal, Vainstein, Vladimir, Ashkenazi, Maayan, Zimran, Eran, Stepensky, Polina, Grisariu, Sigal, and Avni, Batia

Subjects
AUTOGRAFTS, NEUTROPHILS, LYMPHOMAS, NEUTROPENIA, OVERALL survival
Abstract

Neutropenia postchemotherapy is associated with favorable outcomes, which was attributed to optimal dosing. However, little is known about the neutrophil decline rate as a predictor of cancer outcomes, which may reflect a dynamic marker of chemosensitivity. We assessed the association between the neutrophil decline rate and disease outcomes in a known cohort of 212 lymphoma patients, treated with thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan (TECAM) conditioning followed by autologous transplant in our center between 2000 and 2013. Slower neutrophil decline rate was correlated with worse overall survival, mediated not by shorter time to progression (TTP), but rather by worse survival post-progression, possibly pointing to chemosensitivity at each line of therapy as the responsible mechanism. The effect was seen across histologies and was independent of stronger predictors of outcome like performance status (PS) and response before transplant. Prospective research is needed to confirm our results and expand their validity to other clinical scenarios. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results